Merck expands Singapore biosafety testing laboratory to over 1 000 square metres
Merck has expanded its Singapore BioReliance laboratory to over 1 000 square metres adding cell line characterisation and GMP next generation sequencing capabilities for regional biopharma clients
Merck is expanding its Singapore biosafety testing laboratory to over 1,000 square meters, strengthening its analytical and biosafety testing services for customers in the Asia Pacific region. This expansion builds on Merck's 75 years of global testing expertise and is a significant milestone in providing advanced, local contract testing services for the region's growing biopharma industry.
The new facility will offer Cell Line Characterization services, GMP next-generation sequencing (NGS) capabilities, and advanced molecular methods including Blazar®, a proprietary platform for rapid virus detection. This move underscores Merck's commitment to empowering medicine makers by providing industry-leading testing services and technical expertise, and supports Singapore's ecosystem and the region's dynamic life science industry.
Brief written by urgent.news from Vietnam Investment Review's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
